<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Eur J Cancer Care (Engl)</journal-id><journal-id journal-id-type="iso-abbrev">Eur J Cancer Care (Engl)</journal-id><journal-id journal-id-type="doi">10.1111/(ISSN)1365-2354</journal-id><journal-id journal-id-type="publisher-id">ECC</journal-id><journal-title-group><journal-title>European Journal of Cancer Care</journal-title></journal-title-group><issn pub-type="ppub">0961-5423</issn><issn pub-type="epub">1365-2354</issn><publisher><publisher-name>John Wiley and Sons Inc.</publisher-name><publisher-loc>Hoboken</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28393417</article-id><article-id pub-id-type="pmc">5697660</article-id><article-id pub-id-type="doi">10.1111/ecc.12668</article-id><article-id pub-id-type="publisher-id">ECC12668</article-id><article-categories><subj-group subj-group-type="overline"><subject>Original Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Original Articles</subject></subj-group></article-categories><title-group><article-title>Efficacy and safety of fosaprepitant in the prevention of nausea and vomiting following highly emetogenic chemotherapy in Chinese people: A randomized, double&#x02010;blind, phase <styled-content style="fixed-case">III</styled-content> study</article-title></title-group><contrib-group><contrib id="ecc12668-cr-0001" contrib-type="author"><name><surname>Yang</surname><given-names>L.Q.</given-names></name><degrees>MD</degrees><role>Associate Chief Physician</role><xref ref-type="aff" rid="ecc12668-aff-0001">
<sup>1</sup>
</xref><xref ref-type="aff" rid="ecc12668-aff-0002">
<sup>2</sup>
</xref><xref ref-type="author-notes" rid="ecc12668-note-1002">
<sup>&#x02020;</sup>
</xref></contrib><contrib id="ecc12668-cr-0002" contrib-type="author"><name><surname>Sun</surname><given-names>X.C.</given-names></name><degrees>MD</degrees><role>Chief Physician</role><xref ref-type="aff" rid="ecc12668-aff-0001">
<sup>1</sup>
</xref><xref ref-type="aff" rid="ecc12668-aff-0003">
<sup>3</sup>
</xref><xref ref-type="author-notes" rid="ecc12668-note-1002">
<sup>&#x02020;</sup>
</xref></contrib><contrib id="ecc12668-cr-0003" contrib-type="author" corresp="yes"><name><surname>Qin</surname><given-names>S.K.</given-names></name><degrees>MD</degrees><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-8928-6786</contrib-id><role>Chief Physician</role><address><email>qinsk8108@163.com</email></address><xref ref-type="aff" rid="ecc12668-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="ecc12668-cr-0004" contrib-type="author"><name><surname>Cheng</surname><given-names>Y.</given-names></name><degrees>MD</degrees><role>Chief Physician</role><xref ref-type="aff" rid="ecc12668-aff-0004">
<sup>4</sup>
</xref></contrib><contrib id="ecc12668-cr-0005" contrib-type="author"><name><surname>Shi</surname><given-names>J.H.</given-names></name><degrees>MD</degrees><role>Chief Physician</role><xref ref-type="aff" rid="ecc12668-aff-0005">
<sup>5</sup>
</xref></contrib><contrib id="ecc12668-cr-0006" contrib-type="author"><name><surname>Chen</surname><given-names>Z.D.</given-names></name><degrees>MD</degrees><role>Chief Physician</role><xref ref-type="aff" rid="ecc12668-aff-0006">
<sup>6</sup>
</xref></contrib><contrib id="ecc12668-cr-0007" contrib-type="author"><name><surname>Wang</surname><given-names>Q.M.</given-names></name><degrees>MD</degrees><role>Chief Physician</role><xref ref-type="aff" rid="ecc12668-aff-0007">
<sup>7</sup>
</xref></contrib><contrib id="ecc12668-cr-0008" contrib-type="author"><name><surname>Zhang</surname><given-names>H.L.</given-names></name><degrees>MD</degrees><role>Chief Physician</role><xref ref-type="aff" rid="ecc12668-aff-0008">
<sup>8</sup>
</xref></contrib><contrib id="ecc12668-cr-0009" contrib-type="author"><name><surname>Hu</surname><given-names>B.</given-names></name><degrees>MD</degrees><role>Chief Physician</role><xref ref-type="aff" rid="ecc12668-aff-0009">
<sup>9</sup>
</xref></contrib><contrib id="ecc12668-cr-0010" contrib-type="author"><name><surname>Liu</surname><given-names>B.</given-names></name><degrees>MD</degrees><role>Chief Physician</role><xref ref-type="aff" rid="ecc12668-aff-0010">
<sup>10</sup>
</xref></contrib><contrib id="ecc12668-cr-0011" contrib-type="author"><name><surname>Zhang</surname><given-names>Q.Y.</given-names></name><degrees>MD</degrees><role>Chief Physician</role><xref ref-type="aff" rid="ecc12668-aff-0011">
<sup>11</sup>
</xref></contrib><contrib id="ecc12668-cr-0012" contrib-type="author"><name><surname>Wu</surname><given-names>Q.</given-names></name><degrees>MD</degrees><role>Chief Physician</role><xref ref-type="aff" rid="ecc12668-aff-0012">
<sup>12</sup>
</xref></contrib><contrib id="ecc12668-cr-0013" contrib-type="author"><name><surname>Wang</surname><given-names>D.</given-names></name><degrees>MD</degrees><role>Chief Physician</role><xref ref-type="aff" rid="ecc12668-aff-0013">
<sup>13</sup>
</xref></contrib><contrib id="ecc12668-cr-0014" contrib-type="author"><name><surname>Shu</surname><given-names>Y.Q.</given-names></name><degrees>MD</degrees><role>Chief Physician</role><xref ref-type="aff" rid="ecc12668-aff-0003">
<sup>3</sup>
</xref></contrib><contrib id="ecc12668-cr-0015" contrib-type="author"><name><surname>Dong</surname><given-names>J.</given-names></name><degrees>MD</degrees><role>Chief Physician</role><xref ref-type="aff" rid="ecc12668-aff-0014">
<sup>14</sup>
</xref></contrib><contrib id="ecc12668-cr-0016" contrib-type="author"><name><surname>Han</surname><given-names>B.H.</given-names></name><degrees>MD</degrees><role>Chief Physician</role><xref ref-type="aff" rid="ecc12668-aff-0015">
<sup>15</sup>
</xref></contrib><contrib id="ecc12668-cr-0017" contrib-type="author"><name><surname>Wang</surname><given-names>K.M.</given-names></name><degrees>MD</degrees><role>Chief Physician</role><xref ref-type="aff" rid="ecc12668-aff-0016">
<sup>16</sup>
</xref></contrib><contrib id="ecc12668-cr-0018" contrib-type="author"><name><surname>Dang</surname><given-names>C.X.</given-names></name><degrees>MD</degrees><role>Chief Physician</role><xref ref-type="aff" rid="ecc12668-aff-0017">
<sup>17</sup>
</xref></contrib><contrib id="ecc12668-cr-0019" contrib-type="author"><name><surname>Li</surname><given-names>J.L.</given-names></name><degrees>MD</degrees><role>Chief Physician</role><xref ref-type="aff" rid="ecc12668-aff-0018">
<sup>18</sup>
</xref></contrib><contrib id="ecc12668-cr-0020" contrib-type="author"><name><surname>Wang</surname><given-names>H.B.</given-names></name><degrees>MD</degrees><role>Chief Physician</role><xref ref-type="aff" rid="ecc12668-aff-0019">
<sup>19</sup>
</xref></contrib><contrib id="ecc12668-cr-0021" contrib-type="author"><name><surname>Li</surname><given-names>B.L.</given-names></name><degrees>MD</degrees><role>Chief Physician</role><xref ref-type="aff" rid="ecc12668-aff-0020">
<sup>20</sup>
</xref></contrib><contrib id="ecc12668-cr-0022" contrib-type="author"><name><surname>Lu</surname><given-names>J.G.</given-names></name><degrees>MD</degrees><role>Chief Physician</role><xref ref-type="aff" rid="ecc12668-aff-0021">
<sup>21</sup>
</xref></contrib><contrib id="ecc12668-cr-0023" contrib-type="author"><name><surname>Zhang</surname><given-names>Z.H.</given-names></name><degrees>MD</degrees><role>Chief Physician</role><xref ref-type="aff" rid="ecc12668-aff-0022">
<sup>22</sup>
</xref></contrib><contrib id="ecc12668-cr-0024" contrib-type="author"><name><surname>Chen</surname><given-names>Y.X.</given-names></name><degrees>MD</degrees><role>Chief Physician</role><xref ref-type="aff" rid="ecc12668-aff-0002">
<sup>2</sup>
</xref></contrib></contrib-group><aff id="ecc12668-aff-0001">
<label><sup>1</sup></label>
<institution>Nanjing Medical University</institution>
<named-content content-type="city">Nanjing</named-content>
<country country="CN">China</country>
</aff><aff id="ecc12668-aff-0002">
<label><sup>2</sup></label>
<institution>The Affiliated Bayi Hospital of Nanjing University of Chinese Medicine</institution>
<named-content content-type="city">Nanjing</named-content>
<country country="CN">China</country>
</aff><aff id="ecc12668-aff-0003">
<label><sup>3</sup></label>
<institution>The First Affiliated Hospital of Nanjing Medical University</institution>
<named-content content-type="city">Nanjing</named-content>
<country country="CN">China</country>
</aff><aff id="ecc12668-aff-0004">
<label><sup>4</sup></label>
<institution>Jilin Cancer Hospital</institution>
<named-content content-type="city">Changchun</named-content>
<country country="CN">China</country>
</aff><aff id="ecc12668-aff-0005">
<label><sup>5</sup></label>
<institution>Linyi Cancer Hospital</institution>
<named-content content-type="city">Linyi</named-content>
<country country="CN">China</country>
</aff><aff id="ecc12668-aff-0006">
<label><sup>6</sup></label>
<institution>The Second Affiliated Hospital of Anhui Medical University</institution>
<named-content content-type="city">Anhui</named-content>
<country country="CN">China</country>
</aff><aff id="ecc12668-aff-0007">
<label><sup>7</sup></label>
<institution>Henan Cancer Hospital</institution>
<named-content content-type="city">Zhengzhou</named-content>
<country country="CN">China</country>
</aff><aff id="ecc12668-aff-0008">
<label><sup>8</sup></label>
<institution>Tangdu Hospital</institution>
<named-content content-type="city">Xi'an</named-content>
<country country="CN">China</country>
</aff><aff id="ecc12668-aff-0009">
<label><sup>9</sup></label>
<institution>Anhui Provincial Hospital</institution>
<named-content content-type="city">Hefei</named-content>
<country country="CN">China</country>
</aff><aff id="ecc12668-aff-0010">
<label><sup>10</sup></label>
<institution>Shandong Cancer Hospital</institution>
<named-content content-type="city">Qingdao</named-content>
<country country="CN">China</country>
</aff><aff id="ecc12668-aff-0011">
<label><sup>11</sup></label>
<institution>Harbin Medical University Cancer Hospital</institution>
<named-content content-type="city">Harbin</named-content>
<country country="CN">China</country>
</aff><aff id="ecc12668-aff-0012">
<label><sup>12</sup></label>
<institution>The First Affiliated Hospital of Bengbu Medical College</institution>
<named-content content-type="city">Bengbu</named-content>
<country country="CN">China</country>
</aff><aff id="ecc12668-aff-0013">
<label><sup>13</sup></label>
<institution>The Third Affiliated Hospital of Third Military Medical University</institution>
<named-content content-type="city">Chongqing</named-content>
<country country="CN">China</country>
</aff><aff id="ecc12668-aff-0014">
<label><sup>14</sup></label>
<institution>Yunnan Provincial Cancer Hospital</institution>
<named-content content-type="city">Kunming</named-content>
<country country="CN">China</country>
</aff><aff id="ecc12668-aff-0015">
<label><sup>15</sup></label>
<institution>Shanghai Chest Hospital</institution>
<named-content content-type="city">Shanghai</named-content>
<country country="CN">China</country>
</aff><aff id="ecc12668-aff-0016">
<label><sup>16</sup></label>
<institution>The Second Affiliated Hospital of Nanjing Medical University</institution>
<named-content content-type="city">Nanjing</named-content>
<country country="CN">China</country>
</aff><aff id="ecc12668-aff-0017">
<label><sup>17</sup></label>
<institution>The First Affiliated Hospital of Xi'an Jiaotong University</institution>
<named-content content-type="city">Xi'an</named-content>
<country country="CN">China</country>
</aff><aff id="ecc12668-aff-0018">
<label><sup>18</sup></label>
<institution>Cancer Hospital Chinese Academy of Medical Sciences</institution>
<named-content content-type="city">Beijing</named-content>
<country country="CN">China</country>
</aff><aff id="ecc12668-aff-0019">
<label><sup>19</sup></label>
<institution>The Affiliated Hospital of Xuzhou Medical College</institution>
<named-content content-type="city">Xuzhou</named-content>
<country country="CN">China</country>
</aff><aff id="ecc12668-aff-0020">
<label><sup>20</sup></label>
<institution>Beijing Chest Hospital of the Capital Medical College</institution>
<named-content content-type="city">Beijing</named-content>
<country country="CN">China</country>
</aff><aff id="ecc12668-aff-0021">
<label><sup>21</sup></label>
<institution>Nantong Tumor Hospital</institution>
<named-content content-type="city">Nantong</named-content>
<country country="CN">China</country>
</aff><aff id="ecc12668-aff-0022">
<label><sup>22</sup></label>
<institution>Sichuan Province Cancer Hospital</institution>
<named-content content-type="city">Chengdu</named-content>
<country country="CN">China</country>
</aff><author-notes><corresp id="correspondenceTo"><label>*</label><bold>Correspondence</bold><break/>
Shukui Qin, The Affiliated Bayi Hospital of Nanjing University of Chinese Medicine, Nanjing, China.<break/>
Email:<email>qinsk8108@163.com</email><break/></corresp><fn id="ecc12668-note-1002"><label>&#x02020;</label><p>Joint First author.</p></fn></author-notes><pub-date pub-type="epub"><day>10</day><month>4</month><year>2017</year></pub-date><pub-date pub-type="ppub"><month>11</month><year>2017</year></pub-date><volume>26</volume><issue>6</issue><issue-id pub-id-type="doi">10.1111/ecc.2017.26.issue-6</issue-id><issue-title content-type="special-issue-title">Themed section: Bone health and cancer</issue-title><elocation-id>e12668</elocation-id><history><date date-type="accepted"><day>18</day><month>1</month><year>2017</year></date></history><permissions><!--<copyright-statement content-type="issue-copyright"> &#x000a9; 2017 John Wiley & Sons Ltd <copyright-statement>--><copyright-statement content-type="article-copyright">&#x000a9; 2017 The Authors. European Journal of Cancer Care Published by John Wiley &#x00026; Sons Ltd</copyright-statement><license license-type="creativeCommonsBy-nc"><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">Creative Commons Attribution&#x02010;NonCommercial</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.</license-p></license></permissions><self-uri content-type="pdf" xlink:type="simple" xlink:href="file:ECC-26-na.pdf"/><abstract id="ecc12668-abs-0001"><p>The prevention of chemotherapy&#x02010;induced nausea and vomiting was one of the most challenging supportive care issues in oncology, especially to highly emetogenic chemotherapy (<styled-content style="fixed-case">HEC</styled-content>). A total of 645 patients were randomized into fosaprepitant group (fosaprepitant/placebo 150&#x000a0;mg d1 in combination with granisetron and dexamethasone) or aprepitant group (aprepitant/placebo 125&#x000a0;mg d1; 80&#x000a0;mg d2&#x02010;d3 plus granisetron and dexamethasone).The primary endpoint was the percentage of patients who had a complete response (<styled-content style="fixed-case">CR</styled-content>) over the entire treatment course (0&#x02013;120&#x000a0;hr, overall phase [<styled-content style="fixed-case">OP</styled-content>]). It was assessed by using a non&#x02010;inferiority model, with a non&#x02010;inferiority margin of 10%. The difference of the <styled-content style="fixed-case">CR</styled-content> rate was compared between two groups with chi&#x02010;square analysis. Six hundred and twenty&#x02010;six patients were included in the per protocol analysis. The percentage of patients with a <styled-content style="fixed-case">CR</styled-content> in the fosaprepitant group was not inferior to that in the aprepitant group (90.85% versus 94.17%, <italic>p&#x000a0;</italic>=<italic>&#x000a0;</italic>.1302) during <styled-content style="fixed-case">OP</styled-content>. Whether the cisplatin&#x02010;based chemotherapy or not, the <styled-content style="fixed-case">CR</styled-content> rate of the fosaprepitant group was not inferior to that of the aprepitant group. Both regimens were well tolerated. The most common adverse event was constipation. Fosaprepitant provided effective and well&#x02010;tolerated control of nausea and vomiting associated with <styled-content style="fixed-case">HEC</styled-content> in Chinese patients.</p></abstract><kwd-group kwd-group-type="author-generated"><kwd id="ecc12668-kwd-0001">aprepitant</kwd><kwd id="ecc12668-kwd-0002">chemotherapy&#x02010;induced nausea and vomiting</kwd><kwd id="ecc12668-kwd-0003">fosaprepitant</kwd></kwd-group><funding-group><award-group><funding-source>Chia Tai Tianqing Pharmaceutical Group Co., Ltd</funding-source></award-group></funding-group><counts><fig-count count="3"/><table-count count="5"/><page-count count="6"/><word-count count="4123"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>component-id</meta-name><meta-value>ecc12668</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>November 2017</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_NLMPMC version:5.2.6 mode:remove_FC converted:21.11.2017</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="journal" id="ecc12668-cit-1001">
<string-name>
<surname>Yang</surname>
<given-names>LQ</given-names>
</string-name>, <string-name>
<surname>Sun</surname>
<given-names>XC</given-names>
</string-name>, <string-name>
<surname>Qin</surname>
<given-names>SK</given-names>
</string-name>, et&#x000a0;al. <article-title>Efficacy and safety of fosaprepitant in the prevention of nausea and vomiting following highly emetogenic chemotherapy in Chinese people: A randomized, double&#x02010;blind, phase III study</article-title>. <source>Eur J Cancer Care</source>. <year>2017</year>;<volume>26</volume>:<elocation-id>e12668</elocation-id>
<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1111/ecc.12668">https://doi.org/10.1111/ecc.12668</ext-link>
</mixed-citation>
</p><fn-group id="ecc12668-ntgp-0001"><fn fn-type="funding" id="ecc12668-note-0001"><p>
<bold>Funding information</bold>
</p><p>This work was sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd.</p></fn></fn-group></notes></front><body><sec id="ecc12668-sec-0001"><label>1</label><title>INTRODUCTION</title><p>Chemotherapy&#x02010;induced nausea and vomiting (CINV) is the most distressing symptoms experienced by patients with cancer. CINV has a negative impact on the life quality of patients by further diminishing cancer treatment adherence (Sommariva, Pongiglione, &#x00026; Tarricone, <xref rid="ecc12668-bib-0012" ref-type="ref">2016</xref>; Tageja &#x00026; Groninger, <xref rid="ecc12668-bib-0013" ref-type="ref">2016</xref>). Failing adequate antiemetic treatment, more than 90% of patients experience CINV due to highly emetogenic chemotherapy (HEC) (Hesketh, <xref rid="ecc12668-bib-0006" ref-type="ref">2008</xref>).Thus, it is critical to prevent CINV, especially HEC.</p><p>There has been substantial progress in improving the control of CINV since the serotonin 5&#x02010;hydroxytryptamine (5&#x02010;HT<sub>3</sub>) receptor antagonists (RAs)were developed in the 1990s (Gralla et&#x000a0;al., <xref rid="ecc12668-bib-0004" ref-type="ref">1999</xref>). Nevertheless, patients who received HEC but are still suffering from CINV constitute a difficult&#x02010;to&#x02010;treat group. Therefore, new and effective antiemetic agents are needed in controlling CINV. The neurokinin&#x02010;1 receptor (NK&#x02010;1R) is closely involved in CINV, and substance P induces vomiting by binding to NK&#x02010;1R in the central nervous system. This anatomical localization has led to the successful clinical development of antagonists against NK&#x02010;1R in the treatment of CINV (Garcia&#x02010;Recio &#x00026; Gasc&#x000f3;n, <xref rid="ecc12668-bib-0003" ref-type="ref">2015</xref>).</p><p>Both fosaprepitant and aprepitant are potent and selective NK1R antagonists that can improve prevention of CINV in patients receiving moderately emetogenic chemotherapy (MEC) and HEC with the addition to a standard regimen of a 5&#x02010;HT<sub>3</sub> RA and dexamethasone (Langford &#x00026; Chrisp, <xref rid="ecc12668-bib-0009" ref-type="ref">2010</xref>; Ruhlmann &#x00026; Herrstedt, <xref rid="ecc12668-bib-0010" ref-type="ref">2012</xref>). Current guidelines recommend this three&#x02010;drug combination in the control of CINV in patients receiving HEC (Basch et&#x000a0;al., <xref rid="ecc12668-bib-0002" ref-type="ref">2012</xref>; Jordan, Gralla, Jahn, &#x00026; Molassiotis, <xref rid="ecc12668-bib-0008" ref-type="ref">2014</xref>). Fosaprepitant is a water&#x02010;soluble, phosphorylated analog of aprepitant. When administered intravenously, fosaprepitant is rapidly converted to aprepitant. In contrast to aprepitant, fosaprepitant could offer potential benefits for patients who may be unable to tolerate oral administration of antiemetics during an episode of nausea or vomiting (Langford &#x00026; Chrisp, <xref rid="ecc12668-bib-0009" ref-type="ref">2010</xref>).</p><p>Fosaprepitant(EMEND<sup>&#x000ae;</sup>, Merck and Co. Inc.) has been approved by FDA as an alternative to oral aprepitant in 2008. The previous studies were carried out majorly in American, European and African population (Grunberg et&#x000a0;al., <xref rid="ecc12668-bib-0005" ref-type="ref">2011</xref>; Weinstein et&#x000a0;al., <xref rid="ecc12668-bib-0014" ref-type="ref">2016</xref>). However, only limited data pertaining to the use of fosaprepitant is currently available for Chinese and other Asian patients.</p><p>This is the first phase III study to evaluate the efficacy and tolerability of fosaprepitant (Chia Tai Tianqing Pharmaceutical Group Co., Ltd) in patients receiving HEC in China. The antiemetic regimens applied in both groups of the study were designed to be consistent with those applied in a previous trial (Grunberg et&#x000a0;al., <xref rid="ecc12668-bib-0005" ref-type="ref">2011</xref>).</p></sec><sec id="ecc12668-sec-0002"><label>2</label><title>MATERIALS AND METHODS</title><sec id="ecc12668-sec-0003"><label>2.1</label><title>Patients</title><p>Cancer patients who were administered HEC (according to NCCN Clinical Practice Guidelines in Oncology: Antiemesis version 1.2014) were eligible for enrolment in the study. The major emetogenic drugs were used for one day. The required dose of cisplatin was 60&#x000a0;&#x02013;80&#x000a0;mg/m<sup>2</sup> lever in the cisplatin&#x02010;contained regimen. The primary exclusion criteria included uncontrolled nausea (&#x02265;grade 2) and vomiting within 72&#x000a0;hr before chemotherapy initiation and/or HEC given within 2&#x000a0;weeks.</p></sec><sec id="ecc12668-sec-0004"><label>2.2</label><title>Study design</title><p>This was a randomized, active control, double&#x02010;blind, parallel&#x02010;group study, conducted at 21 centres in China. The primary objective was to demonstrate the efficacy of fosaprepitant compared to aprepitant in Chinese patients. Secondary objectives included assessment of the safety and tolerability of the fosaprepitant.</p><p>Patients were randomized in a 1:1 ratio using a central randomization system to receive fosaprepitant (fosaprepitant/placebo 150&#x000a0;mg d1 in combination with granisetron and dexamethasone) or aprepitant (aprepitant/placebo 125&#x000a0;mg d1; 80&#x000a0;mg d2&#x02010;d3 plus granisetron and dexamethasone) (Table&#x000a0;<xref rid="ecc12668-tbl-0001" ref-type="table-wrap">1</xref>).</p><table-wrap id="ecc12668-tbl-0001" xml:lang="en" orientation="portrait" position="float"><label>Table 1</label><caption><p>Study drug schedule</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="top" rowspan="1" colspan="1">Regimen</th><th align="left" valign="top" rowspan="1" colspan="1">Day 1</th><th align="left" valign="top" rowspan="1" colspan="1">Day 2</th><th align="left" valign="top" rowspan="1" colspan="1">Day 3</th><th align="left" valign="top" rowspan="1" colspan="1">Day 4</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Fosaprepitant</td><td align="left" rowspan="1" colspan="1">150&#x000a0;mg IV plus granisetron 3&#x000a0;mg IV plus dexamethasone 6&#x000a0;mg orally or IV</td><td align="left" rowspan="1" colspan="1">Dexamethasone 3.75&#x000a0;mg orally</td><td align="left" rowspan="1" colspan="1">Dexamethasone 3.75&#x000a0;mg orally every 12&#x000a0;hr</td><td align="left" rowspan="1" colspan="1">Dexamethasone 3.75&#x000a0;mg orally every 12&#x000a0;hr</td></tr><tr><td align="left" rowspan="1" colspan="1">Aprepitant</td><td align="left" rowspan="1" colspan="1">125&#x000a0;mg orally plus granisetron 3&#x000a0;mg IV plus dexamethasone 6&#x000a0;mg orally or IV</td><td align="left" rowspan="1" colspan="1">80&#x000a0;mg orally plus dexamethasone 3.75&#x000a0;mg orally</td><td align="left" rowspan="1" colspan="1">80&#x000a0;mg orally plus dexamethasone 3.75&#x000a0;mg orally</td><td align="left" rowspan="1" colspan="1">Dexamethasone 3.75&#x000a0;mg orally</td></tr></tbody></table><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd</copyright-holder></permissions></table-wrap><p>Chemotherapy regimen was required to include high&#x02010;risk emetogenic drugs and the duration for 1&#x000a0;day. All patients provided written informed consent before enrolment into the study. The study protocol was approved by the Ethics Committee Review Board at each participating centre and was registered with <ext-link ext-link-type="uri" xlink:href="http://www.chinadrugtrials.org.cn">www.chinadrugtrials.org.cn</ext-link> (identifier, CTR20140900).</p></sec><sec id="ecc12668-sec-0005"><label>2.3</label><title>Efficacy parameters</title><p>The primary efficacy endpoint was complete response (CR) during the 120&#x000a0;hr after initiation of chemotherapy (overall phase, OP), defined as no vomiting and/or retching with no use of rescue medication.</p><p>Secondary efficacy endpoints included the proportions of subjects who achieved CR during the acute phase and delayed phase (0&#x02013;24 and 25&#x02013;120&#x000a0;hr after chemotherapy initiation, respectively), the time to the first vomiting episode and the frequency of vomiting per day; the time to the first rescue therapy from the chemotherapy initiation (hours) and the proportion of patients receiving rescue therapy; the proportion of patients without significant nausea and the proportion of patients without nausea; the change in ECOG. ECOG was compared per day by Wilcoxon rank sum test between the groups.</p></sec><sec id="ecc12668-sec-0006"><label>2.4</label><title>Study visits and evaluation</title><p>Assessments of efficacy, tolerability and safety variables were performed for 5&#x000a0;days after the start of chemotherapy (0&#x02013;120&#x000a0;hr), including the acute and delayed phase. Global satisfaction in control of nausea was evaluated by patients themselves using 100&#x02010;mm Visual Analog Scale (VAS; 101 point scale, in which 0 represents a condition without nausea and 100 represents a condition with the worst conceivable nausea). No nausea (VAS score, &#x0003c;5mm) and no significant nausea (VAS score, &#x0003c;25mm).</p></sec><sec id="ecc12668-sec-0007"><label>2.5</label><title>Statistical analysis</title><p>The primary efficacy endpoint was assessed using a non&#x02010;inferiority model with a non&#x02010;inferiority margin of 10%. Assuming 75% CR with aprepitant and a difference between treatment groups of &#x02264;10%, 588 patients were required to ensure 80% power of a test. Assuming a 5% dropout rate, 620 patients needed to be enrolled.</p><p>Statistical analyses were performed in the safety set (SS; all patients who received at least one dose of study treatment), the full analysis set (FAS; all SS patients who had &#x02265;1 efficacy assessment) and the per protocol set (PPS; all FAS patients who had no protocol violations that directly affected the primary endpoint). The primary and secondary efficacy endpoints were evaluated with FAS and PPS.</p><p>Chi&#x02010;square was used for statistical analysis. A two&#x02010;sided <italic>p&#x000a0;</italic>&#x0003c;&#x000a0;.05 was considered statistically significant. All analyses were conducted using SAS version 9.3.</p></sec></sec><sec id="ecc12668-sec-0008"><label>3</label><title>RESULTS</title><p>Between November 2014 and July 2015, 645 patients were randomized to the fosaprepitant group (<italic>n</italic>&#x000a0;=&#x000a0;328) or aprepitant group (<italic>n</italic>&#x000a0;=&#x000a0;317). Of these patients, 645 were in the SS, 645 were in the FAS, and 626 were in the PPS (Figure&#x000a0;<xref rid="ecc12668-fig-0001" ref-type="fig">1</xref>).</p><fig fig-type="Figure" xml:lang="en" id="ecc12668-fig-0001" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Study flow chart</p></caption><graphic id="nlm-graphic-1" xlink:href="ECC-26-na-g001"/></fig><p>The baseline demographic, medical characteristics and chemotherapy regimen were comparable between the two groups (Table&#x000a0;<xref rid="ecc12668-tbl-0002" ref-type="table-wrap">2</xref>). The prior chemotherapy included the cisplatin&#x02010;contained regimen, ABVD, AC, etc. The incidence of CINV in the prior chemotherapy was 34.2% (137/401). In the prior cisplatin&#x02010;contained regimen, the incidence of CINV was 37.1% (89/240), whereas that of the prior non&#x02010;cisplatin&#x02010;contained regimen was 29.8% (48/161). In the current chemotherapy, the median cisplatin dose was 73.3&#x000a0;mg/m<sup>2</sup> in the fosaprepitant group and 66.7&#x000a0;mg/m<sup>2</sup> in the aprepitant group. Other non&#x02010;cisplatin HEC regimens were similar between the groups, which included AP, CAP, NP, etc.</p><table-wrap id="ecc12668-tbl-0002" xml:lang="en" orientation="portrait" position="float"><label>Table 2</label><caption><p>Patient baseline characteristics and therapy history: FAS</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="top" rowspan="1" colspan="1"/><th align="char" valign="top" rowspan="1" colspan="1">Fosaprepitant group (<italic>n</italic>&#x000a0;=&#x000a0;328)</th><th align="char" valign="top" rowspan="1" colspan="1">Aprepitant group (<italic>n</italic>&#x000a0;=&#x000a0;317)</th><th align="char" valign="top" rowspan="1" colspan="1">
<italic>p</italic> value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Age, median (range)</td><td align="char" char=" " rowspan="1" colspan="1">55 (20&#x02013;79)</td><td align="char" char=" " rowspan="1" colspan="1">53 (18&#x02013;74)</td><td align="char" char="." rowspan="1" colspan="1">.084</td></tr><tr><td align="left" colspan="4" rowspan="1">Sex</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Male</td><td align="char" char=" " rowspan="1" colspan="1">163 (49.70)</td><td align="char" char=" " rowspan="1" colspan="1">163 (51.42)</td><td align="char" char="." rowspan="1" colspan="1">.694</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Female</td><td align="char" char=" " rowspan="1" colspan="1">165 (50.30)</td><td align="char" char=" " rowspan="1" colspan="1">154 (48.58)</td><td align="char" char=" " rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="4" rowspan="1">ECOG<xref ref-type="fn" rid="ecc12668-note-0300">a</xref>
</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">0</td><td align="char" char=" " rowspan="1" colspan="1">64 (19.57)</td><td align="char" char=" " rowspan="1" colspan="1">64 (20.19)</td><td align="char" char="." rowspan="1" colspan="1">.939</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">1</td><td align="char" char=" " rowspan="1" colspan="1">251 (76.76)</td><td align="char" char=" " rowspan="1" colspan="1">238 (75.08)</td><td align="char" char=" " rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">2</td><td align="char" char=" " rowspan="1" colspan="1">12 (3.67)</td><td align="char" char=" " rowspan="1" colspan="1">15 (4.73)</td><td align="char" char=" " rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="4" rowspan="1">Prior chemotherapy</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">No</td><td align="char" char=" " rowspan="1" colspan="1">121 (36.89)</td><td align="char" char=" " rowspan="1" colspan="1">123 (38.80)</td><td align="char" char="." rowspan="1" colspan="1">.627</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Yes</td><td align="char" char=" " rowspan="1" colspan="1">207 (63.11)</td><td align="char" char=" " rowspan="1" colspan="1">194 (61.20)</td><td align="char" char=" " rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="4" rowspan="1">Prior radiotherapy</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">No</td><td align="char" char=" " rowspan="1" colspan="1">244 (74.39)</td><td align="char" char=" " rowspan="1" colspan="1">256 (80.76)</td><td align="char" char="." rowspan="1" colspan="1">.059</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Yes</td><td align="char" char=" " rowspan="1" colspan="1">84 (25.61)</td><td align="char" char=" " rowspan="1" colspan="1">61 (19.24)</td><td align="char" char=" " rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="4" rowspan="1">Cisplatin&#x02010;contained</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">No</td><td align="char" char=" " rowspan="1" colspan="1">65 (19.8)</td><td align="char" char=" " rowspan="1" colspan="1">83 (26.2)</td><td align="char" char="." rowspan="1" colspan="1">.055</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Yes</td><td align="char" char=" " rowspan="1" colspan="1">263 (80.2)</td><td align="char" char=" " rowspan="1" colspan="1">234 (73.8)</td><td align="char" char=" " rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn id="ecc12668-note-0003"><p>FAS, full analysis set.</p></fn><fn id="ecc12668-note-0300"><label>a</label><p>One data missing in Fosaprepitant group.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd</copyright-holder></permissions></table-wrap><sec id="ecc12668-sec-0009"><label>3.1</label><title>Primary efficacy analysis</title><p>The study met its predefined primary endpoint as fosaprepitant was non&#x02010;inferior to aprepitant. In FAS, CR rate was achieved by 293 (89.33%) patients in the fosaprepitant group and 294 (92.74%) patients in the aprepitant group in the OP. There was no significant difference between the two groups (<italic>p&#x000a0;</italic>=<italic>&#x000a0;</italic>.1330). During the AP, 95.73% of patients in the fosaprepitant group reported CR compared with 95.90% in the aprepitant group (<italic>p&#x000a0;</italic>=<italic>&#x000a0;</italic>1.0000). During the delay phase (DP), 91.16% of patients in the fosaprepitant group reported CR compared with 93.38% in the aprepitant group (<italic>p</italic>&#x000a0;=&#x000a0;.3065). The same conclusion was also drawn from PPS analyses (Figures&#x000a0;<xref rid="ecc12668-fig-0002" ref-type="fig">2</xref> and <xref rid="ecc12668-fig-0003" ref-type="fig">3</xref>).</p><fig fig-type="Figure" xml:lang="en" id="ecc12668-fig-0002" orientation="portrait" position="float"><label>Figure 2</label><caption><p>Percentages of patients achieving complete response (no emesis and no use of rescue therapy) (full analysis set)</p></caption><graphic id="nlm-graphic-3" xlink:href="ECC-26-na-g002"/></fig><fig fig-type="Figure" xml:lang="en" id="ecc12668-fig-0003" orientation="portrait" position="float"><label>Figure 3</label><caption><p>Percentages of patients achieving complete response (no emesis and no use of rescue therapy) (per protocol set). Overall phase was 0&#x02013;120&#x000a0;hr after initation of chemotherapy. Acute phase was 0&#x02013;24&#x000a0;hr after initiation of chemotherapy. Delayed phase was 25&#x02013;120&#x000a0;hr after initiation of chemotherapy</p></caption><graphic id="nlm-graphic-5" xlink:href="ECC-26-na-g003"/></fig><p>In FAS, fosaprepitant was not inferior to aprepitant in the time to rescue therapy (92.73&#x000a0;hr versus 104.02&#x000a0;hr, <italic>p&#x000a0;</italic>=<italic>&#x000a0;</italic>.0458) and the incidence of rescue therapy (6.40% versus 2.84%, <italic>p&#x000a0;</italic>=<italic>&#x000a0;</italic>.0389). For the secondary efficacy endpoints of the incidence of vomiting and nausea, there was no statistical difference (Table&#x000a0;<xref rid="ecc12668-tbl-0003" ref-type="table-wrap">3</xref>). ECOG of per day was compared between the groups and no statistical difference was observed.</p><table-wrap id="ecc12668-tbl-0003" xml:lang="en" orientation="portrait" position="float"><label>Table 3</label><caption><p>Secondary efficacy endpoint comparison</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="top" rowspan="1" colspan="1"/><th align="center" valign="top" rowspan="1" colspan="1">Fosaprepitant group (<italic>n</italic>&#x000a0;=&#x000a0;328)</th><th align="center" valign="top" rowspan="1" colspan="1">Aprepitant group (<italic>n</italic>&#x000a0;=&#x000a0;317)</th><th align="center" valign="top" rowspan="1" colspan="1">
<italic>p</italic> value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">The percentage of vomiting</td><td align="char" char="." rowspan="1" colspan="1">9.76</td><td align="char" char="." rowspan="1" colspan="1">7.26</td><td align="char" char="." rowspan="1" colspan="1">.2647</td></tr><tr><td align="left" rowspan="1" colspan="1">Complete control of vomiting</td><td align="char" char="." rowspan="1" colspan="1">70.73</td><td align="char" char="." rowspan="1" colspan="1">73.50</td><td align="char" char="." rowspan="1" colspan="1">.4825</td></tr><tr><td align="left" rowspan="1" colspan="1">The time to the first vomiting episode (hr)</td><td align="char" char="." rowspan="1" colspan="1">94.07</td><td align="char" char="." rowspan="1" colspan="1">112.23</td><td align="char" char="." rowspan="1" colspan="1">.2647</td></tr><tr><td align="left" rowspan="1" colspan="1">The time to rescue therapy (hr)</td><td align="char" char="." rowspan="1" colspan="1">92.73</td><td align="char" char="." rowspan="1" colspan="1">104.02</td><td align="char" char="." rowspan="1" colspan="1">.0458</td></tr><tr><td align="left" rowspan="1" colspan="1">The percentage of rescue therapy</td><td align="char" char="." rowspan="1" colspan="1">6.40</td><td align="char" char="." rowspan="1" colspan="1">2.84</td><td align="char" char="." rowspan="1" colspan="1">.0389</td></tr><tr><td align="left" rowspan="1" colspan="1">The percentage of no nausea</td><td align="char" char="." rowspan="1" colspan="1">39.94</td><td align="char" char="." rowspan="1" colspan="1">40.69</td><td align="char" char="." rowspan="1" colspan="1">.8726</td></tr></tbody></table><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd</copyright-holder></permissions></table-wrap></sec><sec id="ecc12668-sec-0010"><label>3.2</label><title>Subgroup analysis</title><p>The predefined subgroup analyses included chemotherapy history, sex, age, ECOG, and cisplatin&#x02010;contained regimen. There was no significant difference in terms of CR rate in OP (<italic>p&#x000a0;&#x0003e;&#x000a0;</italic>.05) (Table&#x000a0;<xref rid="ecc12668-tbl-0004" ref-type="table-wrap">4</xref>).</p><table-wrap id="ecc12668-tbl-0004" xml:lang="en" orientation="portrait" position="float"><label>Table 4</label><caption><p>Subgroup analysis of complete response (CR) in overall phase (OP)</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="2" valign="top" colspan="1">Subgroup</th><th align="char" colspan="2" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">Fosaprepitant group</th><th align="char" colspan="2" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">Aprepitant group</th><th align="char" rowspan="2" valign="top" colspan="1">
<italic>p</italic> value</th></tr><tr style="border-bottom:solid 1px #000000"><th align="char" valign="top" rowspan="1" colspan="1">Response (<italic>n</italic>)</th><th align="char" valign="top" rowspan="1" colspan="1">CR (%)</th><th align="char" valign="top" rowspan="1" colspan="1">Response (<italic>n</italic>)</th><th align="char" valign="top" rowspan="1" colspan="1">CR (%)</th></tr></thead><tbody><tr><td align="left" colspan="6" rowspan="1">Prior chemotherapy</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">No</td><td align="char" char="." rowspan="1" colspan="1">102</td><td align="char" char="." rowspan="1" colspan="1">84.30</td><td align="char" char="." rowspan="1" colspan="1">112</td><td align="char" char="." rowspan="1" colspan="1">91.06</td><td align="char" char="." rowspan="1" colspan="1">.1217</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Yes</td><td align="char" char="." rowspan="1" colspan="1">191</td><td align="char" char="." rowspan="1" colspan="1">92.27</td><td align="char" char="." rowspan="1" colspan="1">182</td><td align="char" char="." rowspan="1" colspan="1">93.81</td><td align="char" char="." rowspan="1" colspan="1">.5636</td></tr><tr><td align="left" colspan="6" rowspan="1">Sex</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Male</td><td align="char" char="." rowspan="1" colspan="1">150</td><td align="char" char="." rowspan="1" colspan="1">92.02</td><td align="char" char="." rowspan="1" colspan="1">154</td><td align="char" char="." rowspan="1" colspan="1">94.48</td><td align="char" char="." rowspan="1" colspan="1">.5086</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Female</td><td align="char" char="." rowspan="1" colspan="1">143</td><td align="char" char="." rowspan="1" colspan="1">86.67</td><td align="char" char="." rowspan="1" colspan="1">140</td><td align="char" char="." rowspan="1" colspan="1">90.91</td><td align="char" char="." rowspan="1" colspan="1">.2885</td></tr><tr><td align="left" colspan="6" rowspan="1">Age</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">&#x0003c;65</td><td align="char" char="." rowspan="1" colspan="1">246</td><td align="char" char="." rowspan="1" colspan="1">90.11</td><td align="char" char="." rowspan="1" colspan="1">246</td><td align="char" char="." rowspan="1" colspan="1">92.48</td><td align="char" char="." rowspan="1" colspan="1">.3619</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">&#x02265;65</td><td align="char" char="." rowspan="1" colspan="1">47</td><td align="char" char="." rowspan="1" colspan="1">85.45</td><td align="char" char="." rowspan="1" colspan="1">48</td><td align="char" char="." rowspan="1" colspan="1">94.12</td><td align="char" char="." rowspan="1" colspan="1">.2052</td></tr><tr><td align="left" colspan="6" rowspan="1">ECOG</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">0</td><td align="char" char="." rowspan="1" colspan="1">53</td><td align="char" char="." rowspan="1" colspan="1">82.81</td><td align="char" char="." rowspan="1" colspan="1">59</td><td align="char" char="." rowspan="1" colspan="1">92.19</td><td align="char" char="." rowspan="1" colspan="1">.1802</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">1, 2</td><td align="char" char="." rowspan="1" colspan="1">239</td><td align="char" char="." rowspan="1" colspan="1">90.87</td><td align="char" char="." rowspan="1" colspan="1">235</td><td align="char" char="." rowspan="1" colspan="1">92.89</td><td align="char" char="." rowspan="1" colspan="1">.4251</td></tr><tr><td align="left" colspan="6" rowspan="1">Cisplatin&#x02010;contained</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">No</td><td align="char" char="." rowspan="1" colspan="1">57</td><td align="char" char="." rowspan="1" colspan="1">87.69</td><td align="char" char="." rowspan="1" colspan="1">78</td><td align="char" char="." rowspan="1" colspan="1">93.98</td><td align="char" char="." rowspan="1" colspan="1">.2437</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Yes</td><td align="char" char="." rowspan="1" colspan="1">236</td><td align="char" char="." rowspan="1" colspan="1">89.73</td><td align="char" char="." rowspan="1" colspan="1">216</td><td align="char" char="." rowspan="1" colspan="1">92.31</td><td align="char" char="." rowspan="1" colspan="1">.3501</td></tr></tbody></table><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd</copyright-holder></permissions></table-wrap></sec><sec id="ecc12668-sec-0011"><label>3.3</label><title>Safety analysis</title><p>A total of 645 patients were included in the SS, of whom 319 experienced adverse events (AEs; fosaprepitant: 169/328; aprepitant: 150/317). The study drug&#x02010;related AE for fosaprepitant was similar to that of aprepitant (6.10% versus 7.26%, <italic>p&#x000a0;&#x0003e;&#x000a0;</italic>.05). The most common study drug&#x02010;related AE was constipation, which was reported less frequently in patients receiving fosaprepitant than those receiving aprepitant (3.35% versus 3.15%). The AEs are summarized in Table&#x000a0;<xref rid="ecc12668-tbl-0005" ref-type="table-wrap">5</xref>. All AEs were of mild to moderate severity and tolerable. The incidence of SAE was lower, which only one occurred acute pancreatitis in the aprepitant group, not related to study treatments.</p><table-wrap id="ecc12668-tbl-0005" xml:lang="en" orientation="portrait" position="float"><label>Table 5</label><caption><p>Adverse events (SS)</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="top" rowspan="1" colspan="1">Adverse events</th><th align="center" valign="top" rowspan="1" colspan="1">Fosaprepitant group (<italic>n</italic>&#x000a0;=&#x000a0;328)</th><th align="center" valign="top" rowspan="1" colspan="1">Aprepitant group (<italic>n</italic>&#x000a0;=&#x000a0;317)</th><th align="center" valign="top" rowspan="1" colspan="1">
<italic>p</italic> value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Constipation</td><td align="char" char=" " rowspan="1" colspan="1">11 (3.35)</td><td align="char" char=" " rowspan="1" colspan="1">10 (3.15)</td><td align="char" char="." rowspan="1" colspan="1">1.0000</td></tr><tr><td align="left" rowspan="1" colspan="1">Diarrhoea</td><td align="char" char=" " rowspan="1" colspan="1">1 (0.30)</td><td align="char" char=" " rowspan="1" colspan="1">0 (0)</td><td align="char" char="." rowspan="1" colspan="1">1.0000</td></tr><tr><td align="left" rowspan="1" colspan="1">Distension</td><td align="char" char=" " rowspan="1" colspan="1">1 (0.30)</td><td align="char" char=" " rowspan="1" colspan="1">0 (0)</td><td align="char" char="." rowspan="1" colspan="1">1.0000</td></tr><tr><td align="left" rowspan="1" colspan="1">Headache</td><td align="char" char=" " rowspan="1" colspan="1">1 (0.30)</td><td align="char" char=" " rowspan="1" colspan="1">0 (0)</td><td align="char" char="." rowspan="1" colspan="1">1.0000</td></tr><tr><td align="left" rowspan="1" colspan="1">Anaphylaxis</td><td align="char" char=" " rowspan="1" colspan="1">0 (0.00)</td><td align="char" char=" " rowspan="1" colspan="1">1 (0.32)</td><td align="char" char="." rowspan="1" colspan="1">.4915</td></tr><tr><td align="left" rowspan="1" colspan="1">Hiccup</td><td align="char" char=" " rowspan="1" colspan="1">2 (0.61)</td><td align="char" char=" " rowspan="1" colspan="1">2 (0.63)</td><td align="char" char="." rowspan="1" colspan="1">1.0000</td></tr><tr><td align="left" colspan="4" rowspan="1">Laboratory test and ECG examination</td></tr><tr><td align="left" rowspan="1" colspan="1">White cell count</td><td align="char" char=" " rowspan="1" colspan="1">2 (0.61)</td><td align="char" char=" " rowspan="1" colspan="1">1 (0.32)</td><td align="char" char="." rowspan="1" colspan="1">1.000</td></tr><tr><td align="left" rowspan="1" colspan="1">ALT increasing</td><td align="char" char=" " rowspan="1" colspan="1">1 (0.30)</td><td align="char" char=" " rowspan="1" colspan="1">0 (0.00)</td><td align="char" char="." rowspan="1" colspan="1">1.0000</td></tr><tr><td align="left" rowspan="1" colspan="1">QT interval prolongation</td><td align="char" char=" " rowspan="1" colspan="1">0 (0.00)</td><td align="char" char=" " rowspan="1" colspan="1">2 (0.63)</td><td align="char" char="." rowspan="1" colspan="1">.2412</td></tr></tbody></table><table-wrap-foot><fn id="ecc12668-note-0004"><p>SS, safety set.</p></fn><fn id="ecc12668-note-0005"><p>Values are expressed as <italic>n</italic> (%).</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd</copyright-holder></permissions></table-wrap></sec></sec><sec id="ecc12668-sec-0012"><label>4</label><title>DISCUSSION</title><p>Multiple clinical guidelines including Chinese antiemetic guidelines (2014 version) have recommended antiemetic therapy for HEC consisting of NK&#x02010;1R triple regimen (Gralla et&#x000a0;al., <xref rid="ecc12668-bib-0004" ref-type="ref">1999</xref>; Shiying, Jiliang, &#x00026; Shukui, <xref rid="ecc12668-bib-0011" ref-type="ref">2014</xref>; Tageja &#x00026; Groninger, <xref rid="ecc12668-bib-0013" ref-type="ref">2016</xref>). Aprepitant was the first potent and selective NK1 RA and was also approved for the prevention of CINV by CFDA in China. Compared to 3&#x02010;day oral aprepitant, single&#x02010;dose fosaprepitant was not inferior in terms of efficacy (Grunberg et&#x000a0;al., <xref rid="ecc12668-bib-0005" ref-type="ref">2011</xref>). However, the fosaprepitant regimen greatly simplified the antiemetic regimen which offers more convenient and alternative administration. To our knowledge, no studies have been conducted to directly compare the antiemetic effect of aprepitant with fosaprepitant in Chinese patients.</p><p>This is the first study to provide efficacy and safety data on a single 150&#x000a0;mg dose of fosaprepitant added to a 5&#x02010;HT<sub>3</sub>RA and a corticosteroid in the control of CINV in Chinese patients receiving HEC. On the whole, this single&#x02010;day, triple&#x02010;antiemetic fosaprepitant regimen was not inferior to a standard 3&#x02010;day oral aprepitant regimen in the control of HEC&#x02010;associated CINV.</p><p>In the present phase 3 trials, the CR rate of fosaprepitant in the OP was not inferior to the aprepitant (89.33% versus 92.74%, <italic>p</italic>&#x000a0;=<italic>&#x000a0;</italic>.1330). Especially in the DP, fosaprepitant has also showed good efficacy as it was not inferior to aprepitant in the control of delayed symptoms. The current findings in the Chinese population were consistent with previous reports, demonstrating that fosaprepitant 150&#x02010;mg regimen is not inferior to the aprepitant 3&#x02010;day regimen in the control of CINV in Chinese patients receiving HEC (Grunberg et&#x000a0;al., <xref rid="ecc12668-bib-0005" ref-type="ref">2011</xref>). In contrast to the findings of the EASE study, CR rates in this study were different whether in the OP, AP or DP (Grunberg et&#x000a0;al., <xref rid="ecc12668-bib-0005" ref-type="ref">2011</xref>). However, our results were similar to results of a Japanese study in which the CR rates were achieved in patients receiving cisplatin &#x02265;60&#x000a0;mg/m<sup>2</sup> (Ando et&#x000a0;al., <xref rid="ecc12668-bib-0001" ref-type="ref">2016</xref>). The major reason for the difference was possibly the cisplatin dose. In the EASE study, the CR was achieved in the target population receiving cisplatin &#x02265;70&#x000a0;mg/m<sup>2</sup>. While the patients received non&#x02010;cisplatin HEC regimen or cisplatin &#x02265;60&#x000a0;mg/m<sup>2</sup> which is classified as HEC under treatment guidelines in the current study. In addition, only 25.9% of Asian patients were included in the aforementioned trial. Those results also suggested that differences were present between Asian patients and non&#x02010;Asian patients in the control of CINV, which was possibly related to heterogeneous populations.</p><p>In the present study, for the secondary efficacy endpoints, fosaprepitant was also not inferior to aprepitant in the time to rescue therapy and the incidence of rescue therapy. However, there was no statistical significance in the incidence of nausea between the groups. To our knowledge, nausea is more difficult to control compared to vomiting. At the same time, the incidence of nausea is often underestimated. Though no difference was found in the control of nausea in both groups, more attention should be given to the control of nausea.</p><p>The currently recommended antiemetic therapy is merely based on the emetogenic level of chemotherapy, regardless of the patient's individual risk factors (Hu et&#x000a0;al., <xref rid="ecc12668-bib-0007" ref-type="ref">2016</xref>). No significant difference were found in sex, age and cisplatin&#x02010;contained regimen in terms of CR rate of subgroup analysis in the present study. It still need to develop an approach for personalized management of CINV in the era of precision medicine.</p><p>Fosaprepitant was generally well tolerated, with acceptable AEs. The incidence of AEs related to the study drug was very low&#x02014;6.10% in the fosaprepitant group and 7.26% in aprepitant group. Constipation was the most common AE. The study showed a similar safety profile when compared with previous studies.</p><p>In summary, fosaprepitant is effective and safe in the control of CINV in Chinese patients receiving HEC. It might be a more alternative option as antiemetic therapy.</p></sec></body><back><ref-list content-type="cited-references" id="ecc12668-bibl-0001"><title>REFERENCES</title><ref id="ecc12668-bib-0001"><mixed-citation publication-type="journal" id="ecc12668-cit-0001">
<string-name>
<surname>Ando</surname>, <given-names>Y.</given-names>
</string-name>, <string-name>
<surname>Hayashi</surname>, <given-names>T.</given-names>
</string-name>, <string-name>
<surname>Ito</surname>, <given-names>K.</given-names>
</string-name>, <string-name>
<surname>Suzuki</surname>, <given-names>E.</given-names>
</string-name>, <string-name>
<surname>Mine</surname>, <given-names>N.</given-names>
</string-name>, <string-name>
<surname>Miyamoto</surname>, <given-names>A.</given-names>
</string-name>, &#x02026; <string-name>
<surname>Yamada</surname>, <given-names>S.</given-names>
</string-name> (<year>2016</year>). <article-title>Comparison between 5&#x02010;day aprepitant and single&#x02010;dose fosaprepitant meglumine for preventing nausea and vomiting induced by cisplatin&#x02010;based chemotherapy</article-title>. <source>Supportive Care in Cancer</source>, <volume>24</volume>(<issue>2</issue>), <fpage>871</fpage>&#x02013;<lpage>878</lpage>.<pub-id pub-id-type="pmid">26206077</pub-id></mixed-citation></ref><ref id="ecc12668-bib-0002"><mixed-citation publication-type="journal" id="ecc12668-cit-0002">
<string-name>
<surname>Basch</surname>, <given-names>E.</given-names>
</string-name>, <string-name>
<surname>Prestrud</surname>, <given-names>A. A.</given-names>
</string-name>, <string-name>
<surname>Hesketh</surname>, <given-names>P. J.</given-names>
</string-name>, <string-name>
<surname>Kris</surname>, <given-names>M. G.</given-names>
</string-name>, <string-name>
<surname>Somerfield</surname>, <given-names>M. R.</given-names>
</string-name>, &#x00026; <string-name>
<surname>Lyman</surname>, <given-names>G. H.</given-names>
</string-name> (<year>2012</year>). <article-title>Antiemetic use in oncology: Updated guideline recommendations from ASCO</article-title>. <source>American Society of Clinical Oncology Educational Book</source>, <fpage>532</fpage>&#x02013;<lpage>540</lpage>. doi: <ext-link ext-link-type="doi" xlink:href="10.14694/EdBook_AM.2012.32.532">10.14694/EdBook_AM.2012.32.532</ext-link>
<pub-id pub-id-type="pmid">24451791</pub-id></mixed-citation></ref><ref id="ecc12668-bib-0003"><mixed-citation publication-type="journal" id="ecc12668-cit-0003">
<string-name>
<surname>Garcia&#x02010;Recio</surname>, <given-names>S.</given-names>
</string-name>, &#x00026; <string-name>
<surname>Gasc&#x000f3;n</surname>, <given-names>P.</given-names>
</string-name> (<year>2015</year>). <article-title>Biological and pharmacological aspects of the NK1&#x02010;receptor</article-title>. <source>BioMed Research International</source>, <volume>2015</volume>, <fpage>495704</fpage>.<pub-id pub-id-type="pmid">26421291</pub-id></mixed-citation></ref><ref id="ecc12668-bib-0004"><mixed-citation publication-type="journal" id="ecc12668-cit-0004">
<string-name>
<surname>Gralla</surname>, <given-names>R. J.</given-names>
</string-name>, <string-name>
<surname>Osoba</surname>, <given-names>D.</given-names>
</string-name>, <string-name>
<surname>Kris</surname>, <given-names>M. G.</given-names>
</string-name>, <string-name>
<surname>Kirkbride</surname>, <given-names>P.</given-names>
</string-name>, <string-name>
<surname>Hesketh</surname>, <given-names>P. J.</given-names>
</string-name>, <string-name>
<surname>Chinnery</surname>, <given-names>L. W.</given-names>
</string-name>, &#x02026; <string-name>
<surname>Pfister</surname>, <given-names>D. G.</given-names>
</string-name> (<year>1999</year>). <article-title>Recommendations for the use of antiemetics: Evidence&#x02010;based, clinical practice guidelines. American Society of Clinical Oncology</article-title>. <source>Journal of Clinical Oncology</source>, <volume>17</volume>(<issue>9</issue>), <fpage>2971</fpage>&#x02013;<lpage>2994</lpage>.<pub-id pub-id-type="pmid">10561376</pub-id></mixed-citation></ref><ref id="ecc12668-bib-0005"><mixed-citation publication-type="journal" id="ecc12668-cit-0005">
<string-name>
<surname>Grunberg</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Chua</surname>, <given-names>D.</given-names>
</string-name>, <string-name>
<surname>Maru</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Dinis</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>DeVandry</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Boice</surname>, <given-names>J. A.</given-names>
</string-name>, &#x02026; <string-name>
<surname>Herrstedt</surname>, <given-names>J.</given-names>
</string-name> (<year>2011</year>). <article-title>Single&#x02010;dose fosaprepitant for the prevention of chemotherapy&#x02010;induced nausea and vomiting associated with cisplatin therapy: Randomized, double&#x02010;blind study protocol&#x02013;EASE</article-title>. <source>Journal of Clinical Oncology</source>, <volume>29</volume>(<issue>11</issue>), <fpage>1495</fpage>&#x02013;<lpage>1501</lpage>.<pub-id pub-id-type="pmid">21383291</pub-id></mixed-citation></ref><ref id="ecc12668-bib-0006"><mixed-citation publication-type="journal" id="ecc12668-cit-0006">
<string-name>
<surname>Hesketh</surname>, <given-names>P. J.</given-names>
</string-name> (<year>2008</year>). <article-title>Chemotherapy&#x02010;induced nausea and vomiting</article-title>. <source>New England Journal of Medicine</source>, <volume>358</volume>, <fpage>2482</fpage>&#x02013;<lpage>2494</lpage>.<pub-id pub-id-type="pmid">18525044</pub-id></mixed-citation></ref><ref id="ecc12668-bib-0007"><mixed-citation publication-type="journal" id="ecc12668-cit-0007">
<string-name>
<surname>Hu</surname>, <given-names>Z.</given-names>
</string-name>, <string-name>
<surname>Liang</surname>, <given-names>W.</given-names>
</string-name>, <string-name>
<surname>Yang</surname>, <given-names>Y.</given-names>
</string-name>, <string-name>
<surname>Keefe</surname>, <given-names>D.</given-names>
</string-name>, <string-name>
<surname>Ma</surname>, <given-names>Y.</given-names>
</string-name>, <string-name>
<surname>Zhao</surname>, <given-names>Y.</given-names>
</string-name>, &#x02026; <string-name>
<surname>Zhang</surname>, <given-names>L.</given-names>
</string-name> (<year>2016</year>). <article-title>Personalized estimate of chemotherapy&#x02010;induced nausea and vomiting: Development and external validation of a nomogram in cancer patients receiving highly/moderately emetogenic chemotherapy</article-title>. <source>Medicine (Baltimore)</source>, <volume>95</volume>(<issue>2</issue>), <fpage>e2476</fpage>.<pub-id pub-id-type="pmid">26765450</pub-id></mixed-citation></ref><ref id="ecc12668-bib-0008"><mixed-citation publication-type="journal" id="ecc12668-cit-0008">
<string-name>
<surname>Jordan</surname>, <given-names>K.</given-names>
</string-name>, <string-name>
<surname>Gralla</surname>, <given-names>R.</given-names>
</string-name>, <string-name>
<surname>Jahn</surname>, <given-names>F.</given-names>
</string-name>, &#x00026; <string-name>
<surname>Molassiotis</surname>, <given-names>A.</given-names>
</string-name> (<year>2014</year>). <article-title>International antiemetic guidelines on chemotherapy induced nausea and vomiting (CINV): Content and implementation in daily routine practice</article-title>. <source>European Journal of Pharmacology</source>, <volume>722</volume>, <fpage>197</fpage>&#x02013;<lpage>202</lpage>.<pub-id pub-id-type="pmid">24157984</pub-id></mixed-citation></ref><ref id="ecc12668-bib-0009"><mixed-citation publication-type="journal" id="ecc12668-cit-0009">
<string-name>
<surname>Langford</surname>, <given-names>P.</given-names>
</string-name>, &#x00026; <string-name>
<surname>Chrisp</surname>, <given-names>P.</given-names>
</string-name> (<year>2010</year>). <article-title>Fosaprepitant and aprepitant: An update of the evidence for their place in the prevention of chemotherapy&#x02010;induced nausea and vomiting</article-title>. <source>Core Evid</source>, <volume>5</volume>, <fpage>77</fpage>&#x02013;<lpage>90</lpage>.<pub-id pub-id-type="pmid">21042544</pub-id></mixed-citation></ref><ref id="ecc12668-bib-0010"><mixed-citation publication-type="journal" id="ecc12668-cit-0010">
<string-name>
<surname>Ruhlmann</surname>, <given-names>C. H.</given-names>
</string-name>, &#x00026; <string-name>
<surname>Herrstedt</surname>, <given-names>J.</given-names>
</string-name> (<year>2012</year>). <article-title>Fosaprepitant for the prevention of chemotherapy&#x02010;induced nausea and vomiting</article-title>. <source>Expert Review of Anticancer Therapy</source>, <volume>12</volume>(<issue>2</issue>), <fpage>139</fpage>&#x02013;<lpage>150</lpage>.<pub-id pub-id-type="pmid">22316362</pub-id></mixed-citation></ref><ref id="ecc12668-bib-0011"><mixed-citation publication-type="journal" id="ecc12668-cit-0011">
<string-name>
<surname>Shiying</surname>, <given-names>Y.</given-names>
</string-name>, <string-name>
<surname>Jiliang</surname>, <given-names>Y.</given-names>
</string-name>, &#x00026; <string-name>
<surname>Shukui</surname>, <given-names>Q.</given-names>
</string-name> (<year>2014</year>). <article-title>Antiemetic guidelines on chemotherapy induced vomiting in China. Version 2014</article-title>. <source>Chinese Clinical Oncology</source>, <volume>3</volume>(<issue>19</issue>), <fpage>263</fpage>&#x02013;<lpage>273</lpage>.</mixed-citation></ref><ref id="ecc12668-bib-0012"><mixed-citation publication-type="journal" id="ecc12668-cit-0012">
<string-name>
<surname>Sommariva</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Pongiglione</surname>, <given-names>B.</given-names>
</string-name>, &#x00026; <string-name>
<surname>Tarricone</surname>, <given-names>R.</given-names>
</string-name> (<year>2016</year>). <article-title>Impact of chemotherapy&#x02010;induced nausea and vomiting on health&#x02010;related quality of life and resource utilization: A systematic review</article-title>. <source>Critical Reviews in Oncology/Hematology</source>, <volume>99</volume>, <fpage>13</fpage>&#x02013;<lpage>36</lpage>.<pub-id pub-id-type="pmid">26697988</pub-id></mixed-citation></ref><ref id="ecc12668-bib-0013"><mixed-citation publication-type="journal" id="ecc12668-cit-0013">
<string-name>
<surname>Tageja</surname>, <given-names>N.</given-names>
</string-name>, &#x00026; <string-name>
<surname>Groninger</surname>, <given-names>H.</given-names>
</string-name> (<year>2016</year>). <article-title>Chemotherapy&#x02010;induced nausea and vomiting: An overview and comparison of three consensus guidelines</article-title>. <source>Postgraduate Medical Journal</source>, <volume>92</volume>(<issue>1083</issue>), <fpage>34</fpage>&#x02013;<lpage>40</lpage>.<pub-id pub-id-type="pmid">26561590</pub-id></mixed-citation></ref><ref id="ecc12668-bib-0014"><mixed-citation publication-type="journal" id="ecc12668-cit-0014">
<string-name>
<surname>Weinstein</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<surname>Jordan</surname>, <given-names>K.</given-names>
</string-name>, <string-name>
<surname>Green</surname>, <given-names>S. A.</given-names>
</string-name>, <string-name>
<surname>Camacho</surname>, <given-names>E.</given-names>
</string-name>, <string-name>
<surname>Khanani</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Beckford&#x02010;Brathwaite</surname>, <given-names>E.</given-names>
</string-name>, &#x02026; <string-name>
<surname>Rapoport</surname>, <given-names>B. L.</given-names>
</string-name> (<year>2016</year>). <article-title>Single&#x02010;dose fosaprepitant for the prevention of chemotherapy&#x02010;induced nausea and vomiting associated with moderately emetogenic chemotherapy: Results of a randomized, double&#x02010;blind phase III trial</article-title>. <source>Annals of Oncology</source>, <volume>27</volume>(<issue>1</issue>), <fpage>172</fpage>&#x02013;<lpage>178</lpage>.<pub-id pub-id-type="pmid">26449391</pub-id></mixed-citation></ref></ref-list></back></article>